Skip to main content

Peer Review reports

From: Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

Original Submission
18 Nov 2022 Submitted Original manuscript
16 Jan 2023 Reviewed Reviewer Report - Victor Moreno
21 Jan 2023 Reviewed Reviewer Report - Fedor Moiseenko
2 Feb 2023 Author responded Author comments - Puyuan Xing
Resubmission - Version 2
2 Feb 2023 Submitted Manuscript version 2
13 Feb 2023 Author responded Author comments - Puyuan Xing
Resubmission - Version 3
13 Feb 2023 Submitted Manuscript version 3
Publishing
24 Feb 2023 Editorially accepted
4 Mar 2023 Article published 10.1186/s12885-023-10676-x

You can find further information about peer review here.

Back to article page